Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More
Takeda’s HYQVIA reduces CIDP relapse rates, Phase 3 trial reveals
Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating HYQVIA as a maintenance therapy for adults ... Read More
Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at ... Read More